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Abstract
Human exposure to aluminium is a burgeoning issue. The brain is a sink for systemically available aluminium and a puta-
tive target of neurotoxicity. An increasing number of studies continue to confirm the presence of aluminium in human 
brain tissue though primarily in relation to donors who have died of a neurodegenerative or neurodevelopmental disorder. 
Herein, we have measured aluminium in brain tissue in donors who died of a specific disease or condition though without 
showing any neurodegeneration. The donors were diagnosed as not suffering from multiple sclerosis. Herein, these novel 
data are compared with recent data on aluminium in brain tissue in multiple sclerosis. Brain tissues from all four lobes were 
obtained from the Multiple Sclerosis Society Tissue Bank. Tissues were digested using microwave-assisted acid digestion 
and their aluminium content was measured by transversely heated graphite furnace atomic absorption spectrometry. Both 
are established methods in our laboratory. Detailed statistical analyses were used to compare new data with recent data for 
multiple sclerosis. Aluminium was found in brain tissue in each donor with a high proportion of measurements (189/291) 
being below 1.00 μg/g dry weight. The data for all cases (median and IQR) were 0.74 (0.48–1.28), 1.23 (0.62–1.63), 0.84 
(0.45–1.14) and 1.01 (0.62–1.65) μg/g dry weight for occipital, parietal, temporal and frontal lobes, respectively. There was 
a statistically significant positive correlation between aluminium content of brain tissue and the age of donor. Comparison 
of data for this non-multiple sclerosis group with brain aluminium data for donors dying with a diagnosis of multiple scle-
rosis showed that the latter had a statistically significant higher content of brain aluminium. The data reinforce a previous 
conclusion that the aluminium content of brain tissue in multiple sclerosis is elevated and support the suggestion that human 
exposure to aluminium may have a role to play in the aetiology of multiple sclerosis.
Keywords Human exposure to aluminium · Aluminium in brain tissue · Aluminium in multiple sclerosis · Aluminium and 
neurodegenerative disease · Aluminium and neurodevelopmental disease
Introduction
Human exposure to aluminium is burgeoning (Exley 2013; 
Klotz et al. 2017; Stahl et al. 2017). Humans are living 
in the aluminium age (https ://www.hippo crati cpost .com/
mens-healt h/the-alumi nium-age/) and everyday exposure is 
impacting upon daily life (Cabral Pinto et al. 2018, 2019; 
Stahl et al. 2018; Handra et al. 2019). Systemic aluminium 
is excreted in urine (Michalke et al. 2018) and sweat (Genuis 
et al. 2011) and retained in tissues and especially brain tissue 
(Exley and House 2011). The longevity of neurones predis-
poses them to the accumulation of aluminium though very 
little is understood as to whether higher concentrations of 
aluminium in brain tissue are due to its greater access or 
its increased retention (Exley 2014; Bondy 2016). Ageing 
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is considered a major risk factor for the accumulation of 
aluminium in brain tissue (Roider and Drasch 1999) and 
in itself may underlie a higher content of aluminium in 
brain tissue in sporadic Alzheimer’s disease (House et al. 
2012; Yumoto et al. 2018). There are no other confirmed 
risk factors for the accumulation of aluminium in brain tis-
sue though aluminium is shown to be elevated in a number 
of neurodegenerative and neurodevelopmental disorders 
including familial Alzheimer’s disease (fAD) (Mirza et al. 
2017) and autism spectrum disorder (ASD) (Mold et al. 
2018a). Recently, we made the first analyses of aluminium 
in brain tissue in individuals who died with a diagnosis of 
the neurological condition, multiple sclerosis (MS) (Mold 
et al. 2018b). Our previous research had suggested that indi-
viduals with MS had a higher-than-expected body burden 
of aluminium (Exley et al. 2006; Jones et al. 2017) and this 
prompted us to look for aluminium in MS brain tissue. The 
aluminium content of tissues in MS was found to be univer-
sally high with every donor brain having at least one tissue 
where the measured content of aluminium was considered as 
pathologically significant (≥ 3.00 μg/g dry weight). Detailed 
statistical analyses revealed no relationships with gender or, 
perhaps surprisingly, age of donor. Age was not a risk factor 
for aluminium in brain tissue in MS. Previously, we have 
asked the question as to how much aluminium in brain tis-
sue is too much (Exley and Mold 2019) and this question is 
equally applicable in considering MS. Do we have evidence 
that the aluminium content of brain tissue in MS is high due 
to increased uptake or higher retention? To help in answer-
ing this question, The Multiple Sclerosis Society Tissue 
Bank provided us with brain tissues from donors who did 
not die with a diagnosis of MS and additionally showed no 
neurodegeneration beyond that which could be attributed to 
normal ageing. However, all donors died following a period 
of (usually traumatic) disease and primarily a cancer-related 
condition. There are no data in the current scientific litera-
ture describing aluminium in brain tissue in individuals who 
died of a non-neurodegenerative/non-neurodevelopmental 
disease. Herein, we have made these measurements and 
compared the data with our previous data on MS. We aimed 
to provide further information on aluminium in brain tissue 
in disease and to test if data for MS are, as was previously 
suspected, unusually high.
Materials and Methods
Tissues
Brain tissues were obtained from the Multiple Sclerosis 
Society Tissue Bank, Imperial College, London, follow-
ing ethical approval (NRES Approval No. 08/MRE09/31). 
Donors included three females and nine males between the 
ages of 35 and 88 years. Cancer had played a role in the 
death of at least eight donors. Neuropathological investiga-
tion of all brains revealed no specific neuropathology beyond 
that described as age related. None of the donors had mul-
tiple sclerosis.
Quantitative Measurements
The aluminium content of tissues was measured by an estab-
lished and fully validated method (House et al. 2012) which 
herein is described only briefly. Samples of cortex, between 
0.6 and 5.0 g in weight, were thawed at room temperature 
and cut using a stainless steel blade into sections approxi-
mately 0.3–0.5 g in weight. Tissues were dried for 48 h, to 
a constant weight, in an incubator at 37 °C. Dry and there-
after weighed tissues were digested in a microwave (MARS 
Xpress CEM Microwave Technology Ltd.) in a mixture of 
1 mL 15.8 M  HNO3 (Fisher Analytical Grade) and 1 mL 
30% w/v  H2O2 (BDH Aristar). The resulting digests were 
clear with no fatty residues and, upon cooling, were made 
up to 5 mL volume using ultrapure water (cond. < 0.067 μS/
cm). Total aluminium was measured in each sample by 
transversely heated graphite furnace atomic absorption spec-
trometry (TH GFAAS) using matrix-matched standards and 
an established analytical programme alongside previously 
validated quality assurance data (House et al. 2012). The 
latter included method blanks, detailed descriptions of which 
have been published recently (Exley and Mold 2019).
Statistical Analyses
Data for aluminium content of tissues were skewed and were 
not normally distributed. For descriptive summary statistics, 
the median and interquartile range were calculated for each 
donor and additionally per donor and lobe. For all test sta-
tistics and models, aluminium content data were log trans-
formed. Due to unbalanced groups (non-MS donors = 14, 
MS donors = 12) and unbalanced numbers of samples per 
donor and lobe, mixed effect models including random 
effects for donors and lobe were used.
First, a model was calculated for the non-MS group to 
analyse differences between the factors lobes and gender and 
associations with the covariate age. The model contains all 
these factors as main terms without interactions. Additional 
random effects were nested and included the factor, number 
of samples, nested within lobe and donor.
A second model included the factor group to analyse 
differences between the MS and the non-MS groups (Zuur 
et al. 2009). Data on the hippocampus lobe exist only for 
the non-MS group and were therefore excluded from the 
mixed effect model comparing MS and non-MS donors. We 
considered a p-value smaller than 0.05 to be statistically 
significant. To obtain pairwise differences between lobes 
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and disease groups, post hoc tests with Tukey’s correction 
were performed with the function glht from the R package 
multcomp. For univariate and descriptive analysis, SPSS 
Statistics v.22 (IBM Analytics, Armonk, NY, USA) was 
used; for the mixed effect model, RStudio Version 1.1.463 
© 2009–2018.
Results
Aluminium Content of Brain Tissues
The aluminium content of all tissues ranged from 0.01 
(limit of quantitation) to 17.26 μg/g dry weight (Supple-
mentary Table 1). The latter being a significant outlier and 
originating from the temporal lobe of a 35-year-old male 
who died of cancer of the tongue. The majority of measure-
ments across all four lobes (and occasionally the hippocam-
pus) for all individuals were below 1.00 μg/g dry weight 
(189/291) though 59, 24 and 19 measurements were in the 
range, 1.00–1.99, 2.00–2.99 and ≥ 3.00 μg/g dry weight, 
respectively. There were statistically significant associa-
tions relating to brain aluminium content and age in non-MS 
donors (r(289) = 0.2, p = 0.008, n(samples) = 12, n(samples) = 291, 
Table 2). However the effect of age was weaker in the mul-
tivariate mixed effect model (mixed effect model, p = 0.014, 
n(donors) = 12, n(samples) = 291, Table 2). There were no sig-
nificant differences in brain aluminium content of males 
and females (mixed effect model, p = 0.864, n(donors) = 12, 
n(samples) = 291, Table 2). There were no statistically signifi-
cant differences in aluminium content between lobes (mixed 
effect model, df = 4, p = 0.203, n(donors) = 12, n(samples) = 291, 
Table 2). Regarding the latter, the data for all cases (median 
and IQR) were 0.74 (0.48–1.28), 1.23 (0.62–1.63), 0.84 
(0.45–1.14) and 1.01 (0.62–1.65)  μg/g dry weight for 
occipital, parietal, temporal and frontal lobes, respectively 
(Table 1). There was a significant trend for higher brain alu-
minium content in individuals who died with a diagnosis of 
cancer (8 individuals) compared to other conditions (4 indi-
viduals) (mixed effect model, df = 1, p = 0.004, n(donors) = 12, 
n(samples) = 291, Tables 1 and 2). 
Comparison with Brain Aluminium Content 
in Multiple Sclerosis
The non-MS group and MS group were gender matched 
(Fisher’s exact test, n = 26, p = 0.13) though the former were 
older (t test, p = 0.003, n = 26). There was no statistically 
significant association relating to brain aluminium content 
and age for the MS group (r(330) = 0.03, p = 0.611, n = 14, 
observations = 332). The aluminium content across all lobes 
were significantly higher in MS donors (mixed effect model, 
n(samples) = 615, N(donors) = 26, p = 0.004, Tables 3 and Ta
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4) than non-MS donors (Fig. 1). The single mixed effect 
models per lobe showed a significant difference between MS 
donors and non-MS donors for the frontal lobe (p = 0.012, 
Table 4, Supplementary Table 2, Fig. 2).
Discussion
We report the first measurements of aluminium in human 
brain tissue in donors who died of a non-neurodegenera-
tive or non-neurodevelopmental disorder and whose brain 
showed no recognisable signs of neurodegeneration. These 
are not ‘healthy’ donors, they all died from a serious medi-
cal condition, primarily (8 of the 12 donors) relating to 
cancer. Data covered a wide range of tissue aluminium con-
tent and while a high proportion of tissues, ca 65%, could 
be considered as within a normal or non-pathogenic range 
(< 1.00 μg/g dry weight) ca 7% of tissues had an aluminium 
content considered as pathologically significant (≥ 3.00 μg/g 
dry weight) (Exley and Mold 2019). The donor’s age var-
ied between 35 and 88 years and a statistically significant 
association showed higher brain aluminium content with 
Table 2  Mixed effect model for aluminium content in non-MS donors 
with the fixed factors disease group (non-cancer as reference), lobe 
(occipital as reference), gender (female as reference) and the covari-
ate age 
The random effects include donor, lobe and number of observations. 
Random effects show the veffects of the nested and unbalanced fac-
tors: donor, lobe and sample. The marginal R2 considers only the var-
iance of the fixed effects, while the conditional R2 takes both the fixed 
and random effects into account
 CI confidence interval, df degrees of freedom
Predictors Al levels in brain of all non-MS donors
Estimates CI p-value
(Intercept) − 0.26 −  1.87 to − 0.65  < 0.001
Disease group 0.37 0.14 to 0.59 0.004
Lobe − 0.59 − 0.79 to 0.40 0.203
Age 0.01 − 0.00 to 0.02 0.014
Gender 0.02 − 0.25 to 0.29 0.864
Random effects
Donor: lobe: sample 0.08
n (donor) 12
n (lobe) 5
n (sample) 16
n (total measurements) 291
Marginal R2/conditional R2 0.11/0.24
Table 3  Descriptive statistics of aluminium contents according to the 
disease groups. Number of donors is shown in brackets, IQR (inter-
quartile range). Data for the lobe hippocampus (n(samples) = 8) are 
excluded in this table
Group Number 
of sam-
ples
Min Median IQR Max
MS (n = 14) 332 0.01 1.20 0.44–3.00 132.6
Non-MS (n = 12) 283 0.01 0.61 0.21–1.31 17.3
 Cancer (n = 8) 188 0.01 0.83 0.34–1.61 17.3
 Other (n = 4) 95 0.01 0.38 0.09 -0.93 5.0
Table 4  Full mixed effect model for aluminium content in all donors 
with the fixed factors disease group (non-MS as reference), lobe 
(occipital as reference), gender (female as reference) and the covari-
ate age 
The random effects include donor, lobe and number of samples. 
Random effects show the effects of the nested and unbalanced fac-
tors: donor, lobe and sample. The marginal R2 considers only the 
variance of the fixed effects, while the conditional R2 takes both the 
fixed and random effects into account. Data for the lobe hippocampus 
(n(samples) = 8) are excluded from this analysis
CI Confidence interval, df degrees of freedom, ICC Interclass correla-
tion coefficient
Al levels in brain of all non-MS and MS donors
Predictors* Estimates CI p-value
(Intercept) − 0.63 − 1.22 to − 0.04 0.040
MS 0.38 0.13 to 0.62 0.004
Lobe − 0.49 − 0.51 to 0.38 0.071
Gender − 0.04 − 0.26 to 0.18 0.730
Age 0.00 − 0.00 to 0.01 0.211
Random effects
Donor:lobe:sample 0.16
 n(donor) 26
 n(lobe) 4
 n(sample) 28
 n(total measurements) 615
 Marginal R2/conditional 
R2
0.081/0.284
Fig. 1  Boxplots for aluminium measurements stratified by lobes for 
non-MS and MS groups
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increased age. This finding was opposite to that previously 
observed in MS (Mold et al. 2018b). While it confirmed a 
previous observation of age as a risk factor for brain alu-
minium content in a non-neurologically affected population 
(Roider and Drasch 1999), it also suggests that a correlation 
with age may not be significant in neurologically impaired 
populations. There was a clear significant trend for higher 
brain aluminium content in the eight cancer-related cases 
compared with the four non-cancer-related cases (Tables 1 
and 2). The Multiple Sclerosis Society Tissue Bank pro-
vided the brain tissues investigated herein as possible con-
trol tissues for comparing with aluminium in brain tissue 
in MS. It is certainly true that none of the donors had MS 
or signs of neurodegeneration and while they were slightly 
older than the MS donor group, they were gender matched. 
Detailed statistical analyses showed unequivocally that the 
content of aluminium in brain tissue in MS was significantly 
higher than that in non-MS control group. This is the first 
unequivocal confirmation that aluminium is increased in 
brain tissue in MS (Mold et al. 2018b) and it further sup-
ports the contention that the body burden of aluminium is 
elevated in MS compared to individuals without MS (Exley 
et al. 2006; Jones et al. 2017). The data do not prove a role 
for aluminium in MS, but a higher content of a neurotoxin 
and powerful pro-oxidant (Verstraeten et al. 1997; Exley 
2004) in brain tissue in MS cannot be discarded as a puta-
tive aetiological factor in a disease with both genetic and 
environmental components (Thompson 2017). The results 
also have translational aspects in that they support previous 
research in which silicon-rich mineral waters were suggested 
as potential long-term therapies in treating MS (Jones et al. 
2017).
Acknowledgements Indirect funding to support tissue acquisition and 
some laboratory work came from a grant to Keele University (CE) from 
the Children’s Medical Safety Research Institute (CMSRI), a registered 
charity based in Washington DC, USA. The Multiple Sclerosis Soci-
ety Tissue Bank, funded by the Multiple Sclerosis Society, registered 
charity 207495, supplied tissue samples and the associated clinical and 
neuropathological data.
Compliance with Ethical Standards 
Conflict of interests The authors have no conflicts of interest to report.
Open Access This article is licensed under a Creative Commons Attri-
bution 4.0 International License, which permits use, sharing, adapta-
tion, distribution and reproduction in any medium or format, as long 
as you give appropriate credit to the original author(s) and the source, 
provide a link to the Creative Commons licence, and indicate if changes 
were made. The images or other third party material in this article are 
included in the article’s Creative Commons licence, unless indicated 
otherwise in a credit line to the material. If material is not included in 
the article’s Creative Commons licence and your intended use is not 
permitted by statutory regulation or exceeds the permitted use, you will 
need to obtain permission directly from the copyright holder. To view a 
copy of this licence, visit http://creat iveco mmons .org/licen ses/by/4.0/.
Fig. 2  Boxplots for aluminium measurements stratified by lobes for non-MS and MS groups
 C. Linhart et al.
1 3
References
Bondy SC (2016) Low levels of aluminium can lead to behavioral and 
morphological changes associated with Alzheimer’s disease and 
age-related neurodegeneration. Neurotoxicol 15:222–229
Cabral Pinto MMS, Marinho-Reis P, Almeida A, Ordens CM, Silva 
MM, Freitas S, da Silva EAF (2018) Human predisposition to 
cognitive impairment and its relation with environmental expo-
sure to potentially toxic elements. Environ Geochem Health 
40:1767–1784
Cabral Pinto MMS, Ordens CM, de Melo MTC, Inácio M, Almeida 
A, Pinto E, da Silva EAF (2019) An inter-disciplinary approach 
to evaluate human health risks due to long-term exposure to con-
taminated groundwater near a chemical complex. Expo Health. 
https ://doi.org/10.1007/s1240 3-019-00305 -z
Exley C (2004) The pro-oxidant activity of aluminium. Free Radic 
Biol Med 36:380–387
Exley C (2013) Human exposure to aluminium. Environ Sci 
15:1807–1816
Exley C (2014) Why industry propaganda and political interference 
cannot disguise the inevitable role played by human exposure to 
aluminium in neurodegenerative diseases including Alzheimer’s 
disease. Front Neurol 5:212
Exley C, House E (2011) Aluminium in the human brain. Monat Chem 
142:357–363
Exley C, Mold MJ (2019) Aluminium in human brain tissue: how much 
is too much? J Biol Inorg Chem 24:1279–1282
Exley C, Mamutse G, Korchazhkina O, Pye E, Strekopytov S, Polwart 
A, Hawkins C (2006) Elevated urinary excretion of aluminium 
and iron in multiple sclerosis. Mult Scler 12:533–540
Genuis SJ, Birkholz D, Rodushkin I, Beesoon S (2011) Blood, urine, 
and sweat (BUS) study: monitoring and elimination of bioaccu-
mulated toxic elements. Arch Env Contam Toxicol 61:344–357
Handra CM, Ghita I, Ulmeanu A, Enache AM, Epureanu F, Coman 
OA, Coman L, Fulga I (2019) Depressive clinical manifestations 
associated with professional aluminum exposure. Rev Chim 
70:2162–2167
House E, Esiri M, Forster G, Ince PG, Exley C (2012) Aluminium, 
iron and copper in human brain tissues donated to the medical 
research council’s cognitive function and ageing study. Metal-
lomics 4:56–65
Jones K, Linhart C, Hawkins C, Exley C (2017) Urinary excretion of 
aluminium and silicon in secondary progressive multiple sclero-
sis. EBioMedicine 26:60–67
Klotz K, Weistenhofer W, Neff F, Hartwig A, van Thriel C, Drexler 
H (2017) The health effects of aluminium exposure. Deutsches 
Arzteblatt Int 114:653
Michalke B, Kramer MF, Brehler R (2018) Aluminium (Al) speciation 
in serum and urine after subcutaneous venom immunotherapy 
with Al as adjuvant. J Trace Elem Med Biol 49:178–183
Mirza A, King A, Troakes C, Exley C (2017) Aluminium in brain tissue 
in familial Alzheimer’s disease. J Trace Elem Med Biol 40:30–36
Mold M, Umar D, King A, Exley C (2018a) Aluminium in brain tissue 
in autism. J Trace Elem Med Biol 46:76–82
Mold M, Chmielecka A, Rodriguez MRR, Thom F, Linhart C, King A, 
Exley C (2018b) Aluminium in brain tissue in multiple sclerosis. 
Int J Environ Res Public Health 15:1777
Roider G, Drasch G (1999) Concentration of aluminium in human tis-
sue – investigations on an occupationally non-exposed population 
in southern Bavaria, Germany. Trace Elem Electrolytes 16:77–86
Stahl T, Falk S, Rohrbeck A, Georgii S, Herzog C, Wiegand A, Hotz 
S, Boschek B, Zorn H, Brunn H (2017) Migration of aluminium 
from food contact materials to food-a health risk for consumers? 
Part I of III: exposure to aluminium, release of aluminium, toler-
able weekly intake (TWI), toxicological effects of aluminium, 
study design, and methods. Environ Sci Europe 29:19
Stahl T, Falk S, Taschan H, Boschek B, Brunn H (2018) Evaluation of 
human exposure to aluminium from food and food contact materi-
als. Eur Food Res Technol 244:2077–2084
Thompson AJ (2017) Challenge of progressive multiple sclerosis 
therapy. Curr Opin Neurol 30:237–240
Verstraeten SV, Golub MS, Keen CL, Oteiza PI (1997) Myelin is a 
preferential target of aluminium-mediated oxidative damage. Arch 
Biochem Biophys 344:289–294
Yumoto S, Kakimi S, Ishikawa A (2018) Colocalization of aluminium 
and iron in nuclei of nerve cells in brains of patients with Alzhei-
mer’s disease. J Alzh Dis 65:1267–1281
Zuur AF, Ineo EN, Walker NJ, Saveliev AA, Smith GM (2009) Mixed 
effects models and extensions in ecology with R. Springer, New 
York, p 574
Publisher’s Note Springer Nature remains neutral with regard to 
jurisdictional claims in published maps and institutional affiliations.
